Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC
Revisit the OncLive On Air Episodes From February 2024
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma
Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC
Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma